Seer, Discovery Life Sciences and SCIEX announce

REDWOOD CITY, Calif. And HUNTSVILLE, Alabama and FRAMINGHAM, Mass., January 10, 2022 (GLOBE NEWSWIRE) – Seer Inc. (NASDAQ: SEER), a life science company commercializing a disruptive new platform for proteomics; SCIEX, a world leader in analytical technologies for the life sciences; and Discovery Life Sciences (Discovery), a global leader in the development of biomarkers and biological sample solutions using proteomics, genomics, cells and immunohistochemistry (IHC) technologies, today announced that they have signed an agreement to form the Consortium Proteogenomics, a collaboration that will allow genomics customers to more easily add in-depth and unbiased proteomics data to their discovery, translational and clinical studies. Through this multi-year effort, Discovery will establish, expand and deliver deep and unbiased proteomics capabilities to its existing genomic customers using the Seer Proteograph product suite and the SCIEX ZenoTOF 7600 platform. ‘analysis and cataloging of over a billion peptides each year, enabling the discovery of new protein variants and new biomarkers, potentially leading to therapeutic breakthroughs.

Seer and SCIEX will bring state-of-the-art proprietary proteomics technologies and instruments, and Discovery will bring significant scale and expertise in genomics services and biological samples, to provide services that support plasma proteogenomics projects across the world. population. Seer’s Proteograph product suite includes proprietary engineered nanoparticles, consumables, automation instrument, and software that enables in-depth, unbiased proteomic studies with an unprecedented combination of speed, scale, depth and depth. scope of data. It accurately identifies thousands of proteins and millions of peptides. The SCIEX ZenoTOF 7600 System is an accurate, high-resolution mass system combining the power of Zeno trap pulsation with electron-activated dissolution fragmentation (EAD) technology to uncover previously inaccessible structural information and push the boundaries of quantification achievable with a precise mass. Discovery will expand its existing biomarker discovery platform as part of its proteomics strategy, expanding the technology platforms available to its global customer base. Their unique service-oriented scientific team will provide reliable scientific information for proteogenomic studies.

A graphic accompanying this announcement is available at

“This is a very innovative and groundbreaking partnership in which, for the first time, three industry leaders in science and technology services are dedicating and combining resources at this scale to advance proteogenomics research. This collaboration will overcome existing research challenges and accelerate advancements in our understanding of human health and disease by helping our clients to scale up and dramatically accelerate their multi-omics efforts, ”said Glenn Bilawsky, CEO of Discovery Life Sciences. “The rapid acquisition of data speeds up development. This consortium will provide new large-scale and more comprehensive capabilities to develop and deploy new biomarkers, drug candidates and diagnostics. “

“We are entering a new era where progress is expected at the speed of a pandemic. This collaboration and his commitment to proteogenomic accessibility will help accelerate many new discoveries for disease research. Sensitive detection and robust quantification of biomarkers is the foundation of precision medicine and enables earlier and better diagnosis, as well as more personalized and effective treatments, ”said Joe Fox, president of SCIEX.

“We are delighted to be working with Discovery Life Sciences and SCIEX to bring deep and unbiased proteogenomics to market,” said Omid Farokhzad, CEO and Founder of Seer. “Through our collaboration, we will empower genomics researchers to add deep and unbiased proteomic data to their studies, connecting genotype to phenotype and enabling multi-omics studies of unprecedented resolution. “

The Proteogenomics Consortium aims to dramatically expand our understanding of the proteome in an unbiased manner across a variety of cohorts and disease states. With a phased approach to building a capacity of 100,000 samples per year, the Proteogenomics Consortium plans to create the workflows and expertise necessary to execute large-scale proteogenomics projects efficiently, quickly and robustly. Through the Consortium, there is also an opportunity for future collaborations to further pave the way for the adoption of proteogenomics through workflow optimization and joint publications.

About Discovery Life Sciences

Discovery Life Sciences is the global market leader in the analysis, supply, distribution and services of biospecimen biomarkers for the pharmaceutical, biotechnology and diagnostic industries. HudsonAlpha Discovery is Discovery’s globally recognized sequencing and bioinformatics division that harnesses the latest short and long read genomic analysis technologies to support discovery, translational research and clinical research globally. Driven by science, the Discovery team engages with clients in an innovative and consultative approach to support rapid data acquisition and analysis to support decision making and the deployment of new innovations. We are science at your service. For more information, visit


SCIEX provides solutions for the precision detection and quantification of molecules, enabling our customers to protect and advance the well-being and safety of all. We have been at the forefront of mass spectrometry for 50 years. Since the launch of the very first commercially successful triple quadrupole in 1981, we have developed revolutionary technologies and solutions that influence research and life-changing outcomes.

Today, we continue to provide robust solutions in mass spectrometry and capillary electrophoresis. Our customers are able to respond quickly to environmental risks, better understand disease-related biomarkers, improve clinical patient care, bring relevant drugs to market faster, and maintain healthier and safer foods.

That’s why thousands of life science experts around the world choose SCIEX for answers they can trust to better inform critical decisions that positively impact lives.

For more information, please visit

About seer

Seer is a life sciences company that develops transformative products that open a new door to the proteome. Seer’s Proteograph ™ product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instruments, and software to perform deep, unbiased, large-scale proteomic analysis in hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted lab instrumentation to provide a decentralized solution that can be integrated by almost any lab. The Seer Proteograph suite of products is intended for research use only and is not intended for diagnostic procedures. For more information, please visit

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it as of the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. These statements include, without limitation, statements regarding Seer’s ability to successfully execute the development and commercialization of its proteograph or the combined solution offered by the Consortium Agreement, the ability to analyze and catalog over a billion peptides each year, the discovery of new protein variants, novel biomarkers leading to therapeutic breakthroughs, the ability of the combined product offering to enable laboratories to perform large-scale, impartial, in-depth proteomic studies for deliver new levels of insight, speed, and sensitivity, to expand unbiased proteomics discovery efforts, expand application sets, and future collaborations. These and other risks are described in more detail in documents filed by Seer with the Securities and Exchange Commission (“SEC”) and in other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer makes no commitment to update these statements to reflect events that occur or circumstances that exist after the date on which they were made.

Seer media contact:

Media contact Discovery Life Sciences:

Sciex media contact:

Lulu Van Zandt

Senior Manager, Brand, Public Relations and Social Media

M: +1 (508) 782-9484

Comments are closed.